These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36794237)

  • 1. Immune Response to COVID-19 Vaccination in Hematologic Malignancies: A Mini-Review.
    Keshavarz S; Keshavarz S; Ziamajidi N; Daei S
    Chonnam Med J; 2023 Jan; 59(1):24-30. PubMed ID: 36794237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
    Terpos E; Gavriatopoulou M; Fotiou D; Giatra C; Asimakopoulos I; Dimou M; Sklirou AD; Ntanasis-Stathopoulos I; Darmani I; Briasoulis A; Kastritis E; Angelopoulou M; Baltadakis I; Panayiotidis P; Trougakos IP; Vassilakopoulos TP; Pagoni M; Dimopoulos MA
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
    Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
    Kontandreopoulou CN; Solomou EE; Kolorizos E; Diamantopoulos PT
    Ann Hematol; 2024 Jul; ():. PubMed ID: 39008060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
    Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
    Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
    Chung DJ; Shah GL; Devlin SM; Ramanathan LV; Doddi S; Pessin MS; Hoover E; Marcello LT; Young JC; Boutemine SR; Serrano E; Sharan S; Momotaj S; Margetich L; Bravo CD; Papanicolaou GA; Kamboj M; Mato AR; Roeker LE; Hultcrantz M; Mailankody S; Lesokhin AM; Vardhana SA; Knorr DA
    Blood Cancer Discov; 2021 Nov; 2(6):568-576. PubMed ID: 34778797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia.
    Shadman M; Liu C; Eakle K; Hiew HJ; Biondo JML; Ghia P; Mato AR
    Hemasphere; 2023 Jan; 7(1):e811. PubMed ID: 36570695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Morawska M
    Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.
    Diefenbach C; Caro J; Koide A; Grossbard M; Goldberg JD; Raphael B; Hymes K; Moskovits T; Kreditor M; Kaminetzky D; Fleur-Lominy SS; Choi J; Thannickal SA; Stapleford KA; Koide S
    medRxiv; 2021 Jun; ():. PubMed ID: 34100025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
    Heftdal LD; Hamm SR; Pérez-Alós L; Madsen JR; Armenteros JJA; Fogh K; Kronborg CC; Vallentin AP; Hasselbalch RB; Møller DL; Hansen CB; Pries-Heje M; Gang AO; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Iversen K; Garred P; Nielsen SD; Grønbaek K
    Eur J Haematol; 2023 Aug; 111(2):229-239. PubMed ID: 37151174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
    Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P
    Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.
    Ito Y; Honda A; Kurokawa M
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e691-e707. PubMed ID: 35459624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
    Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
    Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
    Campanella A; Capasso A; Heltai S; Taccetti C; Albi E; Herishanu Y; Haggenburg S; Chatzikonstantinou T; Doubek M; Kättström M; Giannopoulos K; Simkovic M; Moreno C; Massaia M; Bumbea H; Alshemmari S; Ranghetti P; Perotta E; Martini F; Sant'Antonio E; Colia M; Combi C; Levi S; Kater AP; Hazenberg M; Nijhof IS; Hofsink Q; Demosthenous C; Kotaskova J; Zaleska J; Vrbacky F; Raya AM; Bisogno D; Tripoli IE; Popov VM; Roman V; Stavroyianni N; Karypidou M; Scarano E; Locatelli M; Frenquelli M; Scarfò L; Stamatopoulos K; Ghia P
    Am J Hematol; 2024 Apr; 99(4):745-750. PubMed ID: 38264829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination for SARS-CoV-2 in Hematological Patients.
    Riccardi N; Falcone M; Yahav D
    Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
    Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-spike antibody response to the COVID vaccine in lymphoma patients.
    Della Pia A; Kim GYG; Ip A; Ahn J; Liu Y; Kats S; Koropsak M; Lukasik B; Contractor A; Amin K; Ayyagari L; Zhao C; Gupta A; Batistick M; Leslie LA; Goy AH; Feldman TA
    PLoS One; 2022; 17(12):e0266584. PubMed ID: 36454941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
    Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.